MAPS Public Benefit Corporation announced this week that it has submitted a new drug application seeking the approval of MDMA-assisted therapy for the treatment of PTSD.
MAPS is now on track to proposing MDMA as a treatment for PTSD from the FDA in 2024.
Trial found “no serious adverse events were observed in either the MDMA group or the control group.”
MAPS Public Benefit Corporation announced this week that it has submitted a new drug application seeking the approval of MDMA-assisted therapy for the treatment of PTSD.
MAPS is now on track to proposing MDMA as a treatment for PTSD from the FDA in 2024.
Trial found “no serious adverse events were observed in either the MDMA group or the control group.”
Get notified of our the latest cannabis news, exclusive brand deals, events updates and more!